Experts predict that 2026 will bring mixed outcomes in the industry, with caution in investment approaches dominating trends. Concerns about safety versus innovation persist alongside debates on licensing versus M&A. Execution quality is emphasized as crucial, potentially overshadowing compelling scientific narratives. Uncertainty remains about strategic effectiveness in navigating upcoming challenges.
Finding myself with a lengthy layover at the Dublin Airport in Swords, Ireland, on my way to New York from BIO-Europe (and with a surprising lack of Guinness at the…
In July, 2025, GSK (UK) and Hengrui Pharmaceutical (China) executed a $12 billion license and option agreement valued at $12 billion, with $500 million paid upfront. The press release is…
I. Introduction In our industry, not all companies are built for, or even aspire to, worldwide reach. Many are geographically limited, with commercial operations confined to a single country (such…
Introduction One of the benefits of having BIO in Boston is that it provides me with a ~3.5 hour drive back to New York. This gives me a chance to…
Congratulations! You have successfully advanced your drug candidate to the point where it is ready for out-licensing (or so you believe, anyway). You believe that now is the time to…
Why don't companies write business plans anymore? Are they useless? Is it simply faster to put together 10 slides? In this post, we discuss this interesting question.
https://youtu.be/nXkNQpLNz-M We recently completed a Scouting project on behalf of a geographically-focused company. In this video, we discuss some of the lessons learned. We also provide some suggestions for addressing…
Still working on that wave? Like many of you, I am also knee-deep in last minute preparations for BIO. For many of us, this will be the first live partnering…
Easier said than done... Consider the following scenario… You are the CEO of an emerging biotech company. You have managed to raise enough capital to advance a small molecule through…